利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.034 秒)

    Blood group antigen panel
    6.
    发明授权
    Blood group antigen panel 失效
    血型抗原组

    公开(公告)号：US5168043A

    公开(公告)日：1992-12-01

    申请号：US330591

    申请日：1989-03-28

    申请人： Carlos Cordon-Cardo ,  Kenneth O. Lloyd ,  Connie L. Finstad ,  Lloyd J. Old ,  Mryon R. Melamed ,  Joel Sheinfeld

    发明人： Carlos Cordon-Cardo ,  Kenneth O. Lloyd ,  Connie L. Finstad ,  Lloyd J. Old ,  Mryon R. Melamed ,  Joel Sheinfeld

    IPC分类号： C07K16/30 ,  C07K16/34

    CPC分类号： C07K16/30 ,  C07K16/34 ,  Y10S435/96 ,  Y10S436/811 ,  Y10S436/813

    摘要： The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), S8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).

    摘要翻译： 本发明描述了一种确定个体的分泌状态的方法，其包括从个体获得生物流体的样品，并确定样品是否包含Lewisa或Lewisb抗原，样本中Lewisa抗原的存在表明 个体是不分泌者，样本中Lewisb抗原的存在表明个体是分泌体，并且不存在表示个体分泌体状态的抗原是不确定的。 本发明还提供了一种进一步确定具有不确定分泌状态的个体的分泌状态的方法，其包括确定来自个体的生物流体样品是否包含A，B或前体1型链抗原，任何此类抗原存在于 样本表明个体是分泌体，样本中缺少任何这样的抗原，表明个体是非分泌者。 本发明提供了一种确定人类雌性受试者是否易于感染泌尿生殖器感染的方法，其包括根据上述方法确定受试者是否是分泌器，分泌器对这种感染敏感。 本申请还提供了一种从正常组织中分离尿路上皮癌的方法，并将人类生殖细胞肿瘤鉴定为精原细胞瘤或非神经瘤。 最后，本发明提供了包含部分或全部单克隆抗体H29-36（ATCC No.BB8248），S8（ATCC No.HB9036），T174（ATCC No.BB8242），T1818（ATCC No.BB8249），P12（ATCC No.HB8551），F3（ATCC No.HB8217）和K21（ATCC No.HB8549）。

    Method for detecting the presence of G.sub.D3 ganglioside
    10.
    发明授权
    Method for detecting the presence of G.sub.D3 ganglioside 失效
    检测GD3神经节苷脂存在的方法

    公开(公告)号：US4507391A

    公开(公告)日：1985-03-26

    申请号：US365065

    申请日：1982-04-02

    申请人： Clifford S. Pukel ,  Kenneth O. Lloyd ,  Luiz R. Travassos ,  Wolfgang G. Dippold ,  Herbert F. Oettgen ,  Lloyd J. Old

    发明人： Clifford S. Pukel ,  Kenneth O. Lloyd ,  Luiz R. Travassos ,  Wolfgang G. Dippold ,  Herbert F. Oettgen ,  Lloyd J. Old

    IPC分类号： C12Q1/04 ,  G01N33/53 ,  G01N33/574 ,  G01N33/54 ,  C12N15/00

    CPC分类号： G01N33/5743 ,  G01N33/5308 ,  Y10S436/804 ,  Y10S436/811 ,  Y10S436/813 ,  Y10S436/815 ,  Y10S436/828

    摘要： Mouse monoclonal antibody AbR.sub.24 (Dippold et al., Proc. Natl. Acad. Sci. 77:6114-6118, 1980) has a high degree of specificity for human melanoma cells when tested on viable cultured cells using the PA-MHA serological assay. The antigen detected by this antibody has been isolated from melanoma cells and shown to be G.sub.D3 ganglioside by compositional and partial structural analysis and by comparison with authentic G.sub.D3 by thin layer chromatography (TLC). AbR.sub.24 reacts with authentic G.sub.D3, but not with any other ganglioside tested. Using TLC and reactivity with AbR.sub.24, a wide range of cells and tissues was examined for the presence of G.sub.D3. A new serological assay, termed glycolipid-mediated immune adherence (GMIA), was devised for assaying the reactivity of AbR.sub.24 with gangliosides. Melanomas (cultured cells or tumor tissue) were shown to have T.sub.D3 and G.sub.M3 as major gangliosides. Other cells and tissues examined also contained G.sub.D3, but usually only in low amounts. Melanomas (and MOLT-4, a T-cell line) were characterized by a simplified ganglioside profile with G.sub.D3 and G.sub.M3 as major components. The apparent discrepancy between the ubiquitous presence of G.sub.D3 and the serological specificity of AbR.sub.24 for melanoma cells can be explained in terms of localization and concentration of G.sub.D3 in different cells.

    摘要翻译： 当使用PA-MHA血清学测定法在活细胞培养细胞上测试时，小鼠单克隆抗体AbR24（Dippold等人，Proc.Natl.Acad.Sci.77：6114-6118,1980）对人黑素瘤细胞具有高度的特异性。 由该抗体检测到的抗原已从黑素瘤细胞中分离出来，通过组成和部分结构分析显示为GD3神经节苷脂，并通过薄层色谱（TLC）与真实的GD3进行比较。 AbR24与正常的GD3反应，但不与任何其他神经节苷脂检测。 使用TLC和与AbR24的反应性，检查广泛的细胞和组织的GD3的存在。 设计了一种称为糖脂介导的免疫粘附（GMIA）的血清学测定法，用于测定AbR24与神经节苷脂的反应性。 黑色素瘤（培养细胞或肿瘤组织）显示具有TD3和GM3作为主要神经节苷脂。 检查的其他细胞和组织也含有GD3，但通常只有少量。 黑色素瘤（和MOLT-4，T细胞系）以GD3和GM3为主要成分的简化神经节苷脂特征表征。 GD3的普遍存在与黑素瘤细胞的AbR24的血清学特异性之间的明显差异可以根据不同细胞中GD3的定位和浓度来解释。